EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

KYLO-0603, a novel liver-targeting, thyroid hormone receptor-β agonist for the inhibition of MASH progression

Xueqin Lu, Shengjun Wang, Yanchun Du, Bixian Xie, Qingyan Chen, Jinzhen Lin, Bailing Chen, Kunyuan Cui

PLOS One · 2025

DOI: 10.1371/journal.pone.0331768 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS One, 2025. Verfasst von Xueqin Lu und 7 weiteren Autor:innen. Beteiligte Einrichtung: Kylonova (Xiamen) biopharma Co., Ltd, Xiamen, China. Hauptthemen laut MEDLINE: Thyroid Hormone Receptors beta, Liver, Fatty Liver. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Metabolic dysfunction–associated steatohepatitis (MASH) is a progressive liver disease associated with liver-related complications and death. Kylo-0603 is a novel agonist for the thyroid hormone receptor β (THR-β) that has been developed by merging the structures of three acetylgalactosamine (GalNAc)-modified ASPGR ligands with a triiodothyronine (T3) analog. This unique design enables both THR-β activation and targeted delivery to hepatocytes, which significantly reduces the risk of adverse effects related to increased systemic thyroid hormone activity. Additionally, it effectively lowers serum cholesterol levels by as much as 69.2% and low-density lipoprotein cholesterol (LDL-C) levels by up to 88.2% in the MASH mouse model. Meanwhile, Kylo-0603 demonstrated a marked improvement in histological parameters, decreasing steatosis by up to 1.3 points (P < 0.001), inflammation by 1.8 points (P < 0.0001), and ballooning by 0.8 points (P < 0.01). The non-alcoholic steatohepatitis (NASH) activity score (NAS) demonstrated a significant reduction of up to 3.7 points (P < 0.0001), while the fibrosis score decreased by 0.6 points (P < 0.05). These findings indicate that Kylo-0603 effectively ameliorates hepatic MASH pathology and attenuates fibrosis progression. In summary, Kylo-0603-a highly tissue- and target-selective, low-toxicity THR-β agonist—exhibits substantial therapeutic potential for managing MASH and represents a promising novel treatment option for affected patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Thyroid Hormone Receptors betaLiverFatty LiverAnimalsMiceHumansDisease ProgressionMaleDisease Models, AnimalMice, Inbred C57BLHepatocytesNon-alcoholic Fatty Liver Disease

Substanzen

Thyroid Hormone Receptors beta

Autor:innen und Institutionen

  • Kylonova (Xiamen) biopharma Co., Ltd, Xiamen, China.
  • Hygieia pharmaceuticals Co., Ltd, Hangzhou, China.

Zitieren

APA

Lu, X., Wang, S., Du, Y., Xie, B., Chen, Q., Lin, J., Chen, B., & Cui, K. (2025). KYLO-0603, a novel liver-targeting, thyroid hormone receptor-β agonist for the inhibition of MASH progression. PLOS One. https://doi.org/10.1371/journal.pone.0331768

Vancouver

Lu X, Wang S, Du Y, Xie B, Chen Q, Lin J, et al. KYLO-0603, a novel liver-targeting, thyroid hormone receptor-β agonist for the inhibition of MASH progression. PLOS One. 2025. doi:10.1371/journal.pone.0331768

BibTeX
@article{Lu2025,
  author = {Lu, Xueqin and Wang, Shengjun and Du, Yanchun and Xie, Bixian and Chen, Qingyan and Lin, Jinzhen and Chen, Bailing and Cui, Kunyuan},
  title = {KYLO-0603, a novel liver-targeting, thyroid hormone receptor-β agonist for the inhibition of MASH progression},
  journal = {PLOS One},
  year = {2025},
  doi = {10.1371/journal.pone.0331768}
}
Kostenlos starten →